Ceftriaxone
سفتریاکسون
🦠 Antiinfectives For Systemic UseThird-generation cephalosporin
Market / country: 🇺🇸 USA
Rocephin (US)
🧮 Dose calculator
Susceptible bacterial infections (general) · Regimen source: FDA Ceftriaxone · Dosage and Administration, Adults
- • Or in two equal doses. Continue ≥2 days after symptoms resolve; usually 4–14 days; S. pyogenes at least 10 days. FDA Ceftriaxone · Dosage and Administration, Adults
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to ceftriaxone or any cephalosporin; premature neonates up to 41 weeks postmenstrual age; neonates ≤28 days needing calcium-containing IV solutions; IV use of solutions containing lidocaine. FDA Ceftriaxone · Contraindications
Formulations
- IM: reconstituted to 250 mg/mL (per label table) — powder for injection 🇺🇸 USA FDA Ceftriaxone · Dosage and Administration, Intramuscular AdministrationFDA Ceftriaxone · How Supplied
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Ceftriaxone · Pregnancy
“Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Ceftriaxone · Nursing Mothers
“Caution should be exercised when ceftriaxone is administered to a nursing woman.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Ceftriaxone · Pediatric Use
“Safety and effectiveness of ceftriaxone in neonates, infants and pediatric patients have been established for the dosages described in the DOSAGE AND ADMINISTRATION section.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Ceftriaxone · Geriatric Use
“Of the total number of subjects in clinical studies of ceftriaxone, 32% were 60 and over.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA065342
- DailyMed (FDA label)FDA Ceftriaxone
- MedlinePlus (NIH)Ceftriaxone Injection
- WHO ATC/DDDJ01DD04
- Darooyab (Iran)Ceftriaxone
🇮🇷 Registered in Iran Darooyab · G-352/Ceftriaxone
Dosage forms with Iranian generic codes, per Darooyab.
- 00237 · CEFTRIAXONE 1 GR VIAL · ویال سفتریاکسون ۱ گرم
- 00238 · CEFTRIAXONE 250MG VIAL · ویال سفتریاکسون ۲۵۰ میلیگرم
- 13291 · CEFTRIAXONE 2G VIAL · ویال سفتریاکسون ۲ گرم
- 00239 · CEFTRIAXONE 500MG VIAL · ویال سفتریاکسون ۵۰۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Ceftriaxone · Dosage and Administration, Intramuscular AdministrationFDA Ceftriaxone · How SuppliedFDA Ceftriaxone · Dosage and Administration, AdultsFDA Ceftriaxone · Dosage and Administration, Pediatric PatientsFDA Ceftriaxone · ContraindicationsFDA Ceftriaxone · PregnancyFDA Ceftriaxone · Nursing MothersFDA Ceftriaxone · Pediatric UseFDA Ceftriaxone · Geriatric UseFDA Ceftriaxone · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-352/Ceftriaxone
- Clinical review⚠ Unverified